Buy-side · 1–2 weeks · €5k–€7.5k
Quick View
What deserves attention now?
A rapid risk / upside screen for a live or near-term target. Designed to sharpen IC questions and focus deeper diligence.
For PE / Buyers
Understand the commercial risk you are buying — and the value you may be missing.
Revenue Execution tests how the commercial business actually works: the quality of revenue, concentration, pricing, pipeline, management capability, owner dependency, growth credibility and the operating conditions required to capture upside after close.
Buy-side
Test the investment case.
“What could undermine the thesis — and where is hidden value?”
Traditional performance can look healthy while the engine underneath it is fragile. We test sustainability, transferability and execution risk — then separate genuine upside from attractive but unproven management narrative.
Buy-side · 3–5 weeks · €20k–€35k
Comprehensive
How sustainable and transferable is performance?
Evidence-led commercial assessment covering risk, revenue quality, growth credibility, pricing, owner dependency, commercial systems and hidden upside.
Buy-side · 2–4 weeks · €10k–€15k
Not-Ready View
What has to change before this is investable?
For a business you like but cannot yet underwrite with confidence. Converts a rejection into milestones and a structured path to reassessment.
Transaction journey
Initial review → Screen / Diligence → IC decision → Close / Stop
Revenue Execution
Diagnose → Plan; Execute can follow post-close if separately scoped.
Buyer value
Clearer underwriting, sharper challenge, less surprise and a better starting point for value creation.
Sell-side · portfolio exit
See the asset through the next buyer's eyes.
“What could weaken exit value or buyer confidence if we went to market now?”
For PE firms preparing a portfolio company for exit, the work focuses on evidence, management preparedness, value-defence risks and the commercial claims that need to survive buyer scrutiny.
Portfolio exit · 1–2 weeks · €5k–€7.5k
Quick View
Where are the avoidable pressure points?
Fast buyer-eye review of the commercial story before the process becomes expensive and time-pressured.
Portfolio exit · 4–6 weeks · €20k–€30k
Comprehensive
Can management defend the story?
Deeper exit-readiness assessment with evidence validation, management challenge preparation and a remediation roadmap.
Transaction journey
Portfolio exit decision → Prepare asset → Buyer scrutiny → Transaction
Revenue Execution
Diagnose → Plan → Execute as required
PE value
Surface issues before buyers, strengthen evidence and prepare management to defend the commercial reality.
Illustrative buy-side case
Risk and opportunity can be the same finding.
A weak commercial discipline may reduce confidence in today's performance while creating a very real post-close improvement opportunity.
Redwood — €14.8m B2B target
Healthy business. Strong niche. But the underwriting case depends on whether repeat revenue is genuinely durable and whether management can replace founder-led growth.
68%Repeat / contracted
42%Top-5 concentration
~47%Founder in significant wins
14.2%EBITDA margin
Risk
Founder dependency weakens transferability and confidence in pipeline continuity.
Evidence gap
Management's recurring-revenue description requires finer segmentation and historic validation.
Hidden value
Pricing governance and account expansion are immature relative to the installed customer base.
Deal implication
Proceed with clearer assumptions, focused management questions and explicit 100-day priorities.
Illustrative only. Opportunity themes are hypotheses until supported by evidence; no valuation uplift is implied.
FAQ
Questions PE teams should ask.
The assessment is designed to complement, not imitate, the rest of the diligence workstream.
How is this different from traditional CDD?
The emphasis is on how the commercial system actually operates: revenue quality, transferability, owner dependency, sales execution, pricing, forecast credibility, evidence and post-close value-creation implications. Market CDD can sit alongside it where required.
Can you work alongside financial or market diligence providers?
Yes. The scope is explicitly bounded so the work complements financial, legal, tax, market, technical and cyber diligence rather than duplicating it.
How do you test management's growth assumptions?
By tracing the plan back to historical conversion, customer behaviour, capacity, pricing, channel performance, sales productivity and the evidence supporting management's stated assumptions.
How do you assess revenue quality?
We look beyond labels such as recurring or repeat to test concentration, tenure, retention, renewal behaviour, contract structure, dependency, margin, expansion and the evidence trail behind the revenue.
How do you identify hidden value?
We look for underexploited commercial levers such as pricing, account expansion, proposition, recurring-revenue potential, channel, sales productivity and management systems — then separate evidence from inference and unvalidated hypothesis.
What if the business is good but commercially immature?
That is the purpose of the Not-Ready View: identify what has to change, what evidence needs to build and when the asset should be reassessed.
Can findings become the post-acquisition plan?
Yes. Comprehensive work can produce initial 100-day priorities. Full post-close execution is a separate scope and is deliberately not bundled into the diligence engagement.
Can Revenue Execution help management execute after close?
Potentially, yes. Diagnose → Plan → Execute is the core method, but post-close execution is separately scoped and is not part of the current V1 package layer.
For PE / Buyers
Know what you are underwriting before you own it.
Tell us where you are in the deal and what decision you need to make. We will map the right depth of assessment to the transaction.